The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study
Article first published online: 28 JUN 2008
Volume 3, Issue 4, pages 243–246, July 1997
How to Cite
Cohen, G., Elad, S., Or, R., Galili, D. and Garfunkel, A.A. (1997), The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Diseases, 3: 243–246. doi: 10.1111/j.1601-0825.1997.tb00049.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Received 16 January 1997; revised 2 June and 17 July 1997; accepted 17 July 1997
- bone marrow transplantation;
OBJECTIVE: The examination of prophylactic efficacy of tretinoin on oral mucositis, post bone marrow transplantation (BMT).
PATIENTS AND METHODS: The study population consisted of 11 patients undergoing BMT.Six tretinoin topically-treated patients (0.25 mg daily of 0.1 % tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirementS. Concomitant follow-up included conditioning parameters associated with mucositis and engraftment.
RESULTS: The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1.5 vs 3.6; P < 0.02). In the majority of cases the duration of the most severe phase of oral mucositis was shorter in the tretinoin-treated group as compared with the control. Only one patient in the experimental group required morphine analgesics compared with four patients in the control group.
CONCLUSIONS: This preliminary study indicates that the severity of oral mucositis, both objective and subjective, in BMT patients may be reduced by 0.1% topical tretinoin cream, 0.25 mg, administered daily from the beginning of the BMT conditioning regimen until marrow engraftment.